Last reviewed 2026-05-15 · How we verify

Albumin paclitaxel plus carboplatin

Albumin paclitaxel plus carboplatin is a chemotherapy Small molecule drug developed by Chinese Society of Lung Cancer. It is currently in Phase 2 development for Non-small cell lung cancer. Also known as: Abraxane(Albumin-bound paclitaxel,nab-P).

Albumin paclitaxel is a formulation of paclitaxel, a microtubule inhibitor, which works by binding to tubulin and preventing the formation of microtubules, thereby inhibiting cell division. Carboplatin is a platinum-based chemotherapy drug that works by cross-linking DNA, thereby inhibiting cell division.

Albumin paclitaxel is a formulation of paclitaxel, a microtubule inhibitor, which works by binding to tubulin and preventing the formation of microtubules, thereby inhibiting cell division. Carboplatin is a platinum-based chemotherapy drug that works by cross-linking DNA, thereby inhibiting cell division. Used for Non-small cell lung cancer.

At a glance

Mechanism of action

Paclitaxel's mechanism of action is to bind to tubulin and prevent the formation of microtubules, which are essential for cell division. This leads to cell cycle arrest and apoptosis in rapidly dividing cells, such as cancer cells. Carboplatin, on the other hand, works by cross-linking DNA, which prevents the replication of DNA and transcription of RNA, ultimately leading to cell death.

Approved indications

• Non-small cell lung cancer

Common side effects

• Neutropenia
• Anemia
• Thrombocytopenia
• Nausea and vomiting
• Diarrhea

Key clinical trials

• Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
• A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
• Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
• Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (PHASE3)
• A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (PHASE1)
• A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors (PHASE1, PHASE2)
• Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial (PHASE3)
• Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Albumin paclitaxel plus carboplatin CI brief — competitive landscape report
• Albumin paclitaxel plus carboplatin updates RSS · CI watch RSS
• Chinese Society of Lung Cancer portfolio CI

Frequently asked questions about Albumin paclitaxel plus carboplatin

Related

• Drug class: All chemotherapy drugs
• Manufacturer: Chinese Society of Lung Cancer — full pipeline
• Therapeutic area: All drugs in Oncology
• Indication: Drugs for Non-small cell lung cancer
• Also known as: Abraxane(Albumin-bound paclitaxel,nab-P)
• Compare: Albumin paclitaxel plus carboplatin vs similar drugs
• Pricing: Albumin paclitaxel plus carboplatin cost, discount & access